



SHL/SEC/2021

January 21, 2021

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Company Code: 537253

Dear Sir/Ma'am,

Sub. : Outcome of the 243rd Board Meeting held on 21.01.2021.


Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Thursday January 21, 2021, the meeting was started at 03:30 p.m. and concluded at 5.00p.m.

- 1. Approved Unaudited Financial Results (Standalone & consolidated) for the third quarter/nine months ended December 31, 2020 of the Financial Year 2020-21 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).**


You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,
for Sunil Healthcare Limited


Santosh Kumar Sharma
Company Secretary
FCS-6817

Encl : As above



Page 1 of 1

Sunil Healthcare Limited

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662

**SUNIL HEALTHCARE LIMITED**

Registered Office
38E/252-A, Vijay Tower, Shahpurjat
New Delhi-110049

Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com

CIN : L24302DL1973PLC189662


ANNEXURE-1**STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2020**

Rs. in Lakhs

		Standalone					Year Ended Standalone	Consolidated					Year Ended Consolidated
		Quarter ended		Nine Months Ended				Quarter ended		Nine Months Ended			
		31st December 2020	30th September 2020	31st December 2019	31st December 2020	31st December 2019	31st March 2020	31st December 2020	30th September 2020	31st December 2019	31st December 2020	31st December 2019	31st March 2020
Particulars		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	2,330.81	2,267.24	1,886.63	6,698.23	5,440.55	7,012.93	2,250.98	2,285.04	1,905.78	6,699.42	5,394.10	7,002.12
2	Other Income	366.31	52.84	82.91	433.59	1,286.91	1,497.77	359.97	66.10	84.23	439.09	1,290.08	1,467.86
3	Total Income (1+2)	2,697.12	2,320.08	1,969.54	7,131.82	6,727.46	8,510.70	2,610.95	2,351.14	1,990.01	7,138.51	6,684.18	8,469.98
4	Expenses												
	a) Cost of Materials consumed	834.26	790.10	872.23	2,273.90	2,776.47	3,547.51	834.26	790.10	872.23	2,273.90	2,808.36	3,547.51
	b) Purchase of Stock-in-trade	0.48	-	-	0.48	-	0.24	0.48	-	-	0.48	-	0.24
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	560.30	130.09	(32.35)	1,028.09	(534.50)	(657.41)	500.84	122.57	(35.40)	975.05	(619.48)	(736.87)
	d) Employees benefit expenses	316.98	311.79	319.84	937.65	952.06	1,301.74	316.98	311.79	319.84	937.65	952.06	1,301.74
	e) Finance Costs	102.39	144.25	170.11	393.21	524.15	695.43	102.39	144.25	167.59	393.21	524.15	695.43
	f) Depreciation and amortisation	154.91	154.04	154.20	460.59	448.64	612.69	154.92	154.06	154.23	460.63	448.74	612.82
	g) Other Expenses	716.86	782.65	485.24	2,018.16	2,680.72	3,232.32	703.73	812.63	503.34	2,102.40	2,743.30	3,349.06
	Total Expenses	2,686.18	2,312.92	1,969.27	7,112.08	6,847.54	8,732.52	2,613.60	2,335.40	1,981.83	7,143.32	6,857.13	8,769.94
5	Profit before tax from Continuing Operation(3-4)	10.94	7.16	0.27	19.74	(120.08)	(221.82)	(2.65)	15.74	8.18	(4.81)	(172.95)	(299.96)
6	Tax Expenses (Net)	(3.41)	0.91	-	(0.92)	-	(65.00)	(4.59)	1.74	0.64	(0.78)	1.57	(63.40)
	a) Current Tax	-	-	-	-	-	-	-	-	-	-	-	-
	i)-Current Tax	-	-	-	-	-	-	(1.18)	0.83	0.64	0.14	1.57	1.60
	ii)-Tax for Earlier Period	4.64	-	-	4.64	-	-	4.64	-	-	4.64	-	-
	b) Deferred Tax Charged/(Credit)	(8.05)	0.91	-	(5.56)	-	(65.00)	(8.05)	0.91	-	(5.56)	-	(65.00)
7	Profit/(loss) after tax from Continuing Operation	14.35	6.25	0.27	20.66	(120.08)	(156.82)	1.94	14.00	7.54	(4.03)	(174.52)	(236.56)
8	Profit /(Loss) before tax from Discontinued Operations	-	-	-	-	6.54	(359.94)	-	-	-	-	6.54	(359.94)
	Tax expenses from Discontinued Operations	-	-	-	-	-	(100.14)	-	-	-	-	-	(100.14)
	Profit/(Loss) after tax from Discontinued Operations	-	-	-	-	6.54	(259.80)	-	-	-	-	6.54	(259.80)
	Profit/(Loss) after tax	14.35	6.25	0.27	20.66	(113.54)	(416.62)	1.94	14.00	7.54	(4.03)	(167.98)	(496.36)
9	Other Comprehensive Income (OCI)	-	-	-	-	-	280.42	(44.17)	1.20	(14.88)	(44.68)	(13.79)	-
	a) Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	280.42	-	-	-	-	-	280.42
	b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	(44.17)	1.20	(14.88)	(44.68)	(13.79)	(3.36)
10	Total Comprehensive Income	14.35	6.25	0.27	20.66	(113.54)	(136.20)	(42.23)	15.20	(7.34)	(48.71)	(181.77)	(219.30)
11	Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
12	Other Equity	-	-	-	-	-	3,752.27	-	-	-	-	-	3,434.35
13	Earning per share of Rs.10/- each(not annualised)(Continuing Operation)												
	(a) Basic (Rs.)	0.14	0.06	0.00	0.20	(1.17)	(1.53)	0.02	0.14	0.07	(0.04)	(1.70)	(2.31)
	(b) Diluted (Rs.)	0.14	0.06	0.00	0.20	(1.17)	(1.53)	0.02	0.14	0.07	(0.04)	(1.70)	(2.31)
	Earning per share of Rs.10/- each(not annualised)(Discontinued Operation)												
	(a) Basic (Rs.)	-	-	-	-	0.06	(2.53)	-	-	-	-	0.06	(2.53)
	(b) Diluted (Rs.)	-	-	-	-	0.06	(2.53)	-	-	-	-	0.06	(2.53)
	Earning per share of Rs.10/- each(not annualised)												
	(a) Basic (Rs.)	0.14	0.06	0.00	0.20	(1.11)	(4.06)	0.02	0.14	0.07	(0.04)	(1.64)	(4.84)
	(b) Diluted (Rs.)	0.14	0.06	0.00	0.20	(1.11)	(4.06)	0.02	0.14	0.07	(0.04)	(1.64)	(4.84)

- 1 COVID - 19 pandemic has caused serious disruption on the global economic and business environment. There is a huge uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these Financial results on the carrying value of its assets and liabilities as on 31.12.2020. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of these assets and to discharge its obligation adequate liquidity is available. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
- 2 Consequent to decision taken by Board of Directors to phase out " marketing of Food product" in previous year. Accordingly, the Company has exited from marketing of food products and losses of the discontinued business has been disclosed under "Profit/(Loss) from discontinued operations" separately. At the quarter end, the Company has no liability to be paid and no assets to realise related to this business.
- 3 The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.
- 4 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on January 21, 2021 .

Place: NEW DELHI
Date: 21/01/2021



Anil Khaitan
(Chairman cum Managing Director)
DIN 00759951

JKVS & CO.

Chartered Accountants

Review Report on unaudited standalone quarterly and nine months ended financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter and nine months ended December 31, 2020. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: January 21, 2021



For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E


Sajal Goyal
Partner

Membership No. 523903
UDIN: 21523903AAAAAR4797

Independent Auditor's Review Report on consolidated unaudited quarterly and nine months ended financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2020, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following subsidiaries ,
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)




JKVS & CO.

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total revenue from operation of Rs. (19.15) Lakhs and Rs. 258.01 Lakhs, profit/(loss) after tax of Rs. 8.27 Lakhs and Rs. (22.99) Lakhs and total comprehensive income of Rs. (35.91) Lakhs and Rs. (67.68) Lakhs for the quarter and nine months ended December 31, 2020 respectively as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: New Delhi
Date: January 21, 2021



For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E


Sajal Goyal
Partner

Membership No. 523903
UDIN: 21523903AAAAAS4195